Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is poised for growth primarily due to its strong initiatives, including an expanded agreement with STEMCELL Technologies for rhCollagen supply and the appointment of a new U.S. Head of Commercial Operations aimed at boosting North American sales. The company’s differentiation in the market is underscored by the positive performance data for its Collink.3D product, which shows enhanced tissue formation capabilities, finally positioning it favorably against established competitors. Additionally, the operationalization of a U.S.-based logistics center stands to drive incremental sales in both the BioInk and rhCollagen segments, while a new distribution agreement in Poland further broadens the geographical footprint of its products across Europe.

Bears say

CollPlant Biotechnologies Ltd faces challenges due to its reliance on a limited product portfolio and collaborations, which may hinder revenue diversification and long-term growth prospects. Additionally, the company's dependence on emerging markets for its BioInk and rhCollagen products entails risks associated with market acceptance and regulatory hurdles, potentially impacting sales trajectories. Furthermore, high operational costs and ongoing investments in research and development could strain financial resources, resulting in negative cash flow that may affect the company's financial stability.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.